Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06390995 | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 28 | TakedaINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT04439292 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) |
| active not recruiting |
| Phase 2 |
| 44 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jun 12, 2026 |
| clinicaltrials |
| NCT04266912 | Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT00489307 | Dexamethasone for Symptom Burden in Advanced Cancer Patients | active not recruiting | Phase 2 | 132 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03839342 | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations(BEAVER) | active not recruiting | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06400251 | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06351371 | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06357988 | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) | active not recruiting | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360575 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06360588 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) | active not recruiting | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06400238 | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT04439149 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT04439188 | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 27, 2026 | clinicaltrials |
| NCT01628029 | Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer | active not recruiting | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05638295 | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06385496 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06390865 | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06400225 | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 1,123 | DualityBio Inc.INDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT04439110 | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) | active not recruiting | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | May 8, 2026 | clinicaltrials |
| NCT05265091 | A Study of KL590586 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 414 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04439266 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439331 | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439344 | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) | active not recruiting | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 7, 2026 | clinicaltrials |
| NCT04439123 | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT04439175 | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 6, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05490771 | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT01375114 | The Effects of Ginseng on Cancer-Related Fatigue | active not recruiting | Phase 1 / Phase 2 | 165 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06927687 | Study of ZG005 in Patients With Advanced Solid Tumors | active not recruiting | Phase 2 | 50 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03964727 | Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors(TROPiCS-03) | active not recruiting | Phase 2 | 227 | Gilead SciencesINDUSTRY | 8 | Apr 28, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 216 | AkesoINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541001 | PRL3-Zumab in Patients With Advanced Solid Tumors(China Phase II) | active not recruiting | Phase 2 | 60 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04452955 | A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 51 | Intra-IMMUSG Pte LtdINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT02387905 | Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases | active not recruiting | Phase 2 | 87 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04957615 | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03428802 | Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability | active not recruiting | Phase 2 | 21 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06057922 | A Study YL201 in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 990 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 16, 2026source: clinicaltrials